Safety and Efficacy of DIT101 in Relapsed or Refractory Hematologic Malignancies
NCT07485504
·
clinicaltrials.gov ↗
PHASE1
Phase
NOT_YET_RECRUITING
Status
15
Enrollment
INDUSTRY
Sponsor class
Conditions
Relapsed or Refractory Hematologic Malignancies
Interventions
BIOLOGICAL:
In Vivo CAR-T Therapy
Sponsor
Tcelltech Inc.